上药控股山东有限公司

What 上药控股山东有限公司 does

Shanghai Pharmaceuticals Holding Shandong Co., Ltd. (上药控股山东有限公司) is a provincial-level pharmaceutical distribution platform headquartered in Jinan, Shandong Province, operating as a subsidiary of Shanghai Pharmaceuticals Group (SSE: 601607, H: 02607). The company was formed in 2014 through an asset restructuring between Shanghai Pharmaceuticals and Shandong Hongjuitang Pharmaceutical Group, whose predecessor Hongjitang traces its lineage to 1907 and ranks among China's "Three Great Pharmacies" alongside Beijing Tongrentang and Hangzhou Huqingyutang. It distributes over 15,000 pharmaceutical SKUs across 16 product categories to more than 3,000 stable hospital customers throughout Shandong Province, including all Grade-3 hospitals, through 10 wholly-owned municipal subsidiaries and three regional logistics centers in Jinan, Qingdao, and Linyi.

The company operates a vertically integrated pharmaceutical supply chain combining wholesale distribution with a retail pharmacy network of approximately 1,800 stores across 12 provinces. Its proprietary SPD (Supply Processing Distribution) hospital drug supply chain management system, which holds independent intellectual property rights, integrates IoT, RFID, electronic shelf labeling, and barcode technologies to enable end-to-end hospital inventory and procurement management. The system has been deployed at top-tier Shandong hospitals including Shandong TCM University Affiliated Hospital, Shandong University Affiliated Jinan Central Hospital, and Shandong Provincial Hospital. Supporting infrastructure includes ERP, WMS, and a prescription cloud platform (处方云平台).

Revenue is generated through pharmaceutical wholesale distribution under China's transaction-fee model (with prices regulated by the two-invoice system, zero-margin drug policy, 4+7 volume-based procurement, and medical insurance controls), retail pharmacy sales, and value-added services including SPD hospital supply chain management, IVD-SPD diagnostic reagent supply chain services, DTP (Direct-to-Patient) specialty pharmacies, and traditional Chinese medicine decoction services (益药圈). The standalone entity recorded 31.8 billion RMB in tax-free sales revenue in 2016, with the broader Shandong provincial platform reaching 69 billion RMB tax-free. The company pursues a strategic "百亿山东" (10 billion RMB Shandong) objective and serves as one of four pilot provincial platforms under Shanghai Pharmaceuticals' national distribution strategy.

Name

上药控股山东有限公司

Legal name

上药控股山东有限公司

Website

https://sdsph.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Shanghai Pharmaceuticals Holding Shandong is a Jinan-based pharmaceutical distribution platform and provincial subsidiary of Shanghai Pharmaceuticals Group, distributing 15,000+ SKUs to 3,000+ hospitals across Shandong through integrated logistics, proprietary SPD supply chain technology, and 1,800 retail pharmacies nationwide.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Pharmaceutical & Life Sciences Warehousing (GDP-Compliant) (TLAIACAD)

Keywords

• Pharmaceutical distribution
• Pharmaceutical wholesale
• Hospital supply chain
• Retail pharmacy services
• Pharmaceutical logistics

Headquarters

HQ city

Jinan (济南市)

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. 医药分销批发 (Pharmaceutical Distribution & Wholesale): 公司主要从事医药分销批发业务，经营批发抗生素、生化药品、血清、血液制品、疫苗、精神药品、麻醉药品、毒性药品、中药材、中药饮片、中成药、医疗器械、化学试剂、保健食品共计16个门类，15000多个品种、规格。

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

上药控股山东有限公司 is a pharmaceutical distribution and wholesale enterprise that distributes 16 categories and 15,000+ SKUs of pharmaceutical products (including antibiotics, biochemical drugs, blood products, vaccines, TCM materials, decoction pieces, medical devices, chemical reagents, and health foods) to 3,000+ hospitals and medical institutions across Shandong Province. The company operates as a provincial-level platform under Shanghai Pharmaceuticals, with 10 wholly-owned regional subsidiaries, three logistics centers (Jinan, Qingdao, Linyi), and proprietary SPD hospital supply chain management and ERP systems. It also runs nearly 1,800 retail pharmacies across 12 provinces and offers extended pharmaceutical services including DTP pharmacies and IVD-SPD diagnostic supply chain management.

Product overview

上药控股山东有限公司 is a pharmaceutical distribution enterprise operating as a provincial-level platform under Shanghai Pharmaceuticals. The company offers a comprehensive portfolio of healthcare services including pharmaceutical distribution (分销服务), retail pharmacy (零售服务) with nearly 1,800 pharmacies, hospital supply chain management (SPD), R&D innovation, and precision manufacturing. Key service modules include the proprietary SPD hospital drug supply chain management system, 处方云平台 (prescription cloud platform), 益药圈 extended pharmaceutical services, DTP (Direct-to-Patient) pharmacies, and IVD-SPD diagnostic supply chain services. The company distributes 16 categories of products including 15,000+ pharmaceutical SKUs across Shandong Province, serving over 3,000 stable customers including all top-tier hospitals in Shandong.

Differentiator

Problem solved

Functional benefit

Products and services

• Distribution Services (分销服务) Pharmaceutical distribution services covering over 2,500 domestic pharmaceutical manufacturers and 40+ global multinational pharmaceutical companies, serving nearly 10,000 medical institutions nationwide. Core competitive distribution service across Shandong Province and beyond.
• Retail Pharmacy Services (零售服务) Retail pharmacy services with nearly 1,800 pharmacies distributed across 12 provinces and cities, ranking among the top five in national pharmaceutical retail industry by sales scale. Uses modern information technology as a carrier to innovate health service models.
• R&D Innovation (研发创新) Multi-level R&D system centered on the Central Research Institute, with academician-led professional R&D team focused on providing safe and effective therapeutic drugs for major diseases and chronic diseases.
• Lean Manufacturing (精益制造) Rigorous pharmaceutical production quality management implementing lean production standards with advanced and efficient pharmaceutical production facilities to continuously deliver quality, safe and effective medications.
• Hospital Drug Supply Chain Management (SPD) Hospital drug supply chain management system with independent intellectual property rights. Integrates internet of things technology, barcode RFID technology, electronic warehouse label picking technology, and electronic data collectors to enable intelligent lean management of the entire drug supply chain from procurement to clinical consumption. Deployed in 100+ major medical institutions nationally.
• Prescription Cloud Platform (处方云平台) Cloud-based prescription management platform enabling prescription processing, medication guidance, and hospital information connectivity for improved patient medication services.
• IVD-SPD (In Vitro Diagnostic Supply Chain Management) In Vitro Diagnostic supply chain management services providing inventory management and distribution for diagnostic reagents and medical devices to hospitals.
• DTP Pharmacy (Direct-to-Patient Pharmacy) Direct-to-Patient pharmacy services through specialized DTP (Direct-to-Patient) pharmacies providing specialty medications and patient support programs.

Quantifiable outcome

• 平台总规模无税69亿元（2016年），单体销售收入31.8亿元，利润总额7162万元
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles8 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered 重要 and 核心.

• 合肥天麦生物重要GTM or Marketing Partner · 17 September 2019合肥天麦生物总裁包幼甫先生主持「4+7扩面」高峰论坛，围绕「壮丽70年，奋斗新时代」主题，与核心供应商代表共同探讨医药政策解读及推广实施。
• 山东中医药大学附属医院核心Strategic or Co-development Partner · 19 February 2019SPD医院药品供应链管理项目在山东中医药大学附属医院正式启动，将「互联网+」供应链管理理念引入到医院药品采购及院内管理中，优化重组医院从药品采购、仓储、配送至临床消耗的全供应链管理流程，帮助医院实现药品供应链全程的智能精益化管理。
• 博莱科（Bracco）重要Strategic or Co-development Partner · 1 January 2019博莱科合作项目沟通会上，博莱科项目代表就产品、项目、山东销售潜力与目标、双方合作优势及模式进行了详细介绍，推进双方在山东市场的合作。
• 上海医药集团核心Strategic or Co-development Partner · 1 August 2018上海医药集团作为母公司，为上药控股山东有限公司提供强大的专业、技术、品种、管理等资源优势，支持省级平台建设。
• 杰特贝林（上海）医药信息咨询有限公司重要Strategic or Co-development Partner · 7 July 2018协办山东省血液制品合理用药高峰论坛（第一期），共同推进血液制品的合理使用及学术交流。
• 上海梅斯医学科技有限公司（MedSci）重要Strategic or Co-development Partner · 1 July 2018邀请梅斯医学MedSci专家团队分别为山东中医药大学附属医院药学部量身打造《中药制剂SCI论文写作与发表》专题培训讲座，为山东大学附属济南市中心医院带来系列学术讲座，助力医院科室科研建设。
• 上药医疗供应链管理（上海）有限公司核心Technology or Integration · 1 January 2018上药医疗供应链管理（上海）有限公司业务副总经理曹刚就「IVD-SPD」进行了介绍，推进SPD项目在山东平台的实施。
• 上药云商有限公司重要Technology or Integration · 1 January 2018上药云商有限公司副总经理蒋宇翔进行了「处方云平台」介绍，推进数字化医疗平台在山东的应用。
• 上药控股青岛有限公司核心Strategic or Co-development Partner · 1 January 2018上药控股青岛有限公司作为山东省平台的重要组成部分，于2019年正式纳入省级平台委托管理，在采购、销售、物流、财务、内控等方面实现一体化运营。
• 山东上药商联药业有限公司核心Strategic or Co-development Partner · 1 January 2018山东上药商联药业有限公司作为山东省平台的重要组成部分，于2019年正式纳入省级平台委托管理，共同推进省平台一体化建设。

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Liuzhou Pharmaceutical (柳药股份): Regional A-share listed distributor dominant in Guangxi with hospital supply chain service business model similar to SPD. Comparable in the hospital-channel + supply-chain-extension strategy though serving a different province.
• Yingte Group / Zhejiang Int'l Group (英特集团): Regional pharmaceutical distributor strong in Zhejiang with hospital and retail channels. Comparable in full-line distribution model focused on a single provincial market.
• Nanjing Pharmaceutical (南京医药): Regional pharmaceutical distributor strong in Jiangsu/Anhui with hospital supply chain services. Comparable regional full-line distributor competing in the same tier of city-level hospital market structure.

Direct peers

• China Resources & Great Pharmacy Holdings (重药控股): A-share listed pharmaceutical distributor affiliated with China Resources, dominant in Southwest China. Comparable in hospital-channel full-line distribution and state-owned backing.
• Jointown Pharmaceutical (九州通): A-share listed full-line pharmaceutical distributor with strong lower-tier hospital and primary care penetration. Comparable in business model (full-line wholesale), customer mix (hospitals + retail), and emphasis on logistics technology.
• Sinopharm Group (国药控股): China's largest pharmaceutical distributor with national hospital channel coverage. Directly comparable to 上药控股山东 in core business of hospital-facing drug distribution, including SPD-style supply chain services.
• China Resources Pharmaceutical (华润医药): State-owned pharmaceutical commercial conglomerate operating full-line distribution and retail pharmacy nationwide. Comparable in product breadth (full-line Rx distribution), hospital channel focus, and state-owned backing.
• Cachet Pharmaceutical (嘉事堂): A-share listed pharmaceutical distributor with hospital supply chain extension services. Comparable business model including hospital SPD-style service offerings and specialty drug distribution.
• China Meheco (中国医药): A central state-owned pharmaceutical distributor and trader focused on hospital channel and international pharma trade. Comparable as a direct hospital distributor with specialty drug and import drug capabilities.

Broad incumbents

• Shanghai Pharmaceuticals (上海医药): The parent company (601607.SH / 02607.HK) and one of China's top pharmaceutical commercial groups. Comparable as a broader incumbent — same product categories, hospital distribution model, and SPD/IT system DNA, but at national scale across manufacturing, R&D, distribution and retail.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E4%B8%8A%E8%8D%AF%E6%8E%A7%E8%82%A1%E5%B1%B1%E4%B8%9C%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 上药控股山东有限公司